Holen Sie sich die Stockscreener-App
49.23
0.26%
-0.13
Handel nachbörslich:
49.50
0.27
+0.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$49.36
Offen:
$49.18
24-Stunden-Volumen:
14.24M
Relative Volume:
1.18
Marktkapitalisierung:
$104.46B
Einnahmen:
$48.30B
Nettoeinkommen (Verlust:
$-8.95B
KGV:
-11.14
EPS:
-4.42
Netto-Cashflow:
$13.94B
1W Leistung:
-2.44%
1M Leistung:
-17.94%
6M Leistung:
-7.43%
1J Leistung:
+2.91%
1-Tages-Spanne:
$49.06
$50.09
1-Wochen-Bereich:
$44.93
$51.60
52-Wochen-Spanne:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
49.23 | 104.46B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Bristol Myers (BMY) Gains FDA Nod for Updated Camzyos Label to Simplify Treatment | BMY Stock News - GuruFocus
Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures - TipRanks
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Bristol Myers (BMY) Target Price Trimmed as Revenue Projections Dip | BMY Stock News - GuruFocus
Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know - Yahoo Finance
Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now? - Insider Monkey
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance
Gilead Vs Bristol Myers: Which Biotech Bigwig Is A Better Bet Now? - Barchart.com
Bristol-Myers Squibb (BMY): Potential 19.73% Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Ca - GuruFocus
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis - GuruFocus
Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Bristol Myers stumbles in bid to widen heart drug’s use - BioPharma Dive
BMO maintains Bristol-Myers $61 target after trial setback By Investing.com - Investing.com India
Bristol-Myers stock dips on trial results - Investing.com Australia
BMS’ Camzyos fails to show new cardiomyopathy benefit in Phase III - PharmaLive
OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra - 01net
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III - BioSpace
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis - Quantisnow
Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires? - Insider Monkey
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
BMS Phase III Camzyos trial misses endpoints - The Pharma Letter
Bristol-Myers Squibb: Hold Rating Amid Mixed Financial Signals and Future Prospects - TipRanks
Chemotherapy Market Overall Study Report 2025-2032 | - openPR.com
Bristol Myers (BMY) Reports Unmet Goals in Key Trial for Camzyos - GuruFocus
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Bristol Myers falls as heart disease drug fails in late-stage trial - TradingView
Bristol Myers reports setback in Camzyos heart drug trial - Investing.com
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsight - The Globe and Mail
BMS’ Opdivo combo approved in US for hepatocellular carcinoma - Yahoo Finance
Bristol Myers: new approval for Opdivo+Yervoy - MarketScreener
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week - MedCity News
Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuit - Medical Dialogues
Bristol Myers Squibb (BMY) Secures FDA Approval for Liver Cancer Treatment - GuruFocus
UBS cuts Bristol-Myers Squibb price target to $54 from $60 By Investing.com - Investing.com South Africa
Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods - insights.citeline.com
Bristol-Myers Squibb Faces Q1 Expectations With Eliquis And Revlimid Leading - Finimize
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? - Insider Monkey
Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer - Fierce Pharma
UBS cuts Bristol-Myers Squibb price target to $54 from $60 - Investing.com Australia
Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report - TradingView
Here's What To Expect From Bristol-Myers Squibb's Next Earnings Report - Barchart.com
Dasatinib Drugs Market Deep Research 2025-2032 | Bristol-Myers - openPR.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
10 Best Medical Stocks to Buy According to Billionaires - Insider Monkey
Bristol Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises - MarketScreener
FDA Approves Opdivo (BMY) Plus Yervoy Combo for Colorectal Cance - GuruFocus
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):